Back to search results

Metabolism-Informed Care to Aid Alaska Native People to Quit Smoking (QUIT)

This study is looking at a new way to help Alaska Native and American Indian people quit smoking. It uses a test called the Nicotine Metabolite Ratio (NMR) to help doctors choose the best medicine to help you stop smoking. The study will involve taking blood samples to measure your NMR. We want to see if this approach is practical and helpful in increasing the number of people who successfully quit smoking. You may be able to join if you are an Alaska Native or American Indian person, are 18 or older, smoke daily, and plan to get help quitting through the Southcentral Foundation Quit Tobacco Program. This study aims to enroll 50 participants.

Study design
This is a single-arm pilot study, meaning all participants will receive the same intervention. It plans to enroll 50 participants.
What's involved
You would have blood drawn by clinical staff. Your participation would involve assessments at 6, 12, and 26 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 26 weeks after starting the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06556238

Metabolism-Informed Care to Aid Alaska Native People to Quit Smoking (QUIT)

Recruiting
NAAges 18+InterventionalHealth services
Southcentral Foundation
~50 participants
Updated 2026-04-24 on ClinicalTrials.gov
What's tested:Nicotine Metabolite Ratio

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility of intervention implementation: Enrollment
Measured over Beta phase (n=10) 6 weeks; Pilot phase (n=40) 6 weeks, 12 weeks, 26 weeks
+4 more outcomes measured

Conditions

Smoking Cessation

Explore related trials

Smoking CessationNicotine Metabolite Ratio Measurement

Where it's being run

1 sites across 1 states
Alaska1

Study leadership

  • Georgia J Michlig, PhD · PRINCIPAL_INVESTIGATOR · Southcentral Foundation

Who to contact

Georgia Michlig, PhD
[email protected]
907-729-5421
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Alaska Native or American Indian person by self-report
eligible for or already receiving services at Southcentral Foundation (SCF)
age 18 years or older
daily smoking in the past 30-days
if other nicotine or tobacco products are used, cigarettes are main product used
planning to schedule an appointment with the Quit Tobacco Program to seek smoking cessation treatment in the next 30 days
willing to make a quit attempt within 30 days of enrollment in the Quit Tobacco Program
willing to have a blood test to inform their treatment
willing to try a pharmacologic treatment
willing to provide a saliva sample
has phone service
has access to broadband internet on mobile phone at home, work, or other location
has an Android or iPhone mobile phone compatible with the Smokerlyzer app

Exclusion

Participated in the prior study phase
participated in a cessation program during the past 3 months
their provider has not approved varenicline in their referral to the Quit Tobacco Program
has history of serious hypersensitivity or skin reactions to varenicline
has bleeding disorder or is currently receiving cancer treatment
questionable capacity or impaired decision-making capacity

What this trial measures

  • Feasibility of intervention implementation: EnrollmentBeta phase (n=10) 6 weeks; Pilot phase (n=40) 6 weeks, 12 weeks, 26 weeks

    Proportion of eligible persons who enroll

  • Feasibility of intervention implementation: Treatment recommendationsBeta phase (n=10) 6 weeks; Pilot phase (n=40) 6 weeks, 12 weeks, 26 weeks

    Proportion who use treatment recommended by NMR results

  • Feasibility of intervention implementation: Semi-structured interviewsBeta phase (n=10) 6 weeks; Pilot phase (n=40) 6 weeks, 12 weeks, 26 weeks

    Qualitatively, based on semi-structured interviews with a selection of participants and care team/administrators, thematic analysis will explore barriers and facilitators to using metabolism-informed care, as well as fidelity challenges in adhering to the recommended treatment.

  • Acceptability of metabolism-informed intervention: QuantitativeBeta phase (n=10) 6 weeks; Pilot phase (n=40) 6 weeks, 12 weeks, 26 weeks

    Mean of fourteen, 3-point, Likert-scale survey responses (agree/neither agree nor disagree/disagree, with a "prefer not to answer" option). These items will assess intervention and process acceptability including timeliness of the procedures and recommendation, composition of the team, clarity of communication, ease of understanding pilot measures, willingness to recommend, and satisfaction. These items will be combined into a summary score indicating overall acceptability of the intervention.

  • Acceptability of metabolism-informed intervention: QualitativeBeta phase (n=10) 6 weeks; Pilot phase (n=40) 6 weeks, 12 weeks, 26 weeks

    Additional data will be collected qualitatively via semi-structured interviews with selected participants and care team/administrators.